Catégorie : Medtech

AURORA STERILISATION

by jbertholdin Medtech

AURORA STERILISATION

About the company

Aurora was founded in 2019 by Jan Laarman and Thomas Parias, after 5 years of in-house industrial research, two entrepreneurs passionate about innovation in the field of healthcare. Their goal is to become a major player in the field of sterilization using natural plasma as the sole sterilizing agent.

About the solution

The company develops a unique patent-protected sterilization method based on an oxygen plasma. It enables the sterilization of complex and sensitive devices that can’t be sterilized with existing technologies. It operates at low temperature (30-40°C). It is an environmental-friendly sterilization technology of medical devices.

Aurora Sterilisation’s flagship product is the Aqsaniit sterilizer. Aurora’s technology is eco-friendly, energy-efficient, and non-toxic, addressing both health and environmental concerns.

Website
Key information

–  Therapeutic areas: Medtech

–  Therapeutic areas: Sterilization, endoscopy

–  Based in: Rouen (France)

–  Employees: 11 – 50

–  Created in: 2019

AgenT

by jbertholdin Medtech

AgenT

About the company

AgenT is on a mission to defeat neurodegenerative diseases at their silent stage—before irreversible damage occurs. Built on a decade of research, its proprietary multiomics platform combines proteomics, metabolomics, and AI to create ultra-specific, blood-based diagnostic tests for people aged 50+.

With 103 biomarkers across 9 key pathways, and a major validation study of 4,200+ individuals across 3 continents, AgenT is setting a new standard in early detection. Results are expected in 2026.

Beyond diagnostics, the platform supports drug development, companion diagnostics, and personalized healthcare—positioning AgenT at the forefront of next-generation neurology.

About the solution


AgenT is building a pipeline of first-in-class blood tests to predict and prevent the progression of neurodegenerative and age-related diseases—years before clinical symptoms emerge.

At the foundation is a proprietary biological profiling test that monitors 9 key biological pathways involved in healthy ageing. Designed for individuals aged 55+, it enables early detection of system-level dysregulations to guide preventive care.

Website
Key information

–  Main industry type: Biotech

–  Therapeutic areas: Neurodegenerative diseases

–  Based in: Paris (France)

–  Employees: 1-10

–  Created in: 2018

ROSETTA OMICS

by jbertholdin Biotech, Medtech, Pharma

ROSETTA OMICS

About the company

Rosetta Omics pioneers precision medicine through tumor characterization using spatial multiomics, deep mass spectrometry and AI. Their focus is to optimize first-line treatments by matching therapies with patients effectively, starting with liver and colon cancers. They aim to empower oncologists with a transformative tool, enhancing patient care, and cutting costs. Collaborating with pharma and biotech firms, they seek to identify new biomarkers, accelerating therapeutic and diagnostic innovations.

Committed to scientific advancement and patient well-being, Rosetta Omics is reshaping cancer care. Through cutting-edge technologies and comprehensive multiomics analysis, they provide personalized treatment insights for improved outcomes. Rosetta Omics is at the forefront of precision medicine, driven by innovation, collaboration, and a commitment to saving lives.

About the solution

Their biopsy-based predictive test can be integrated within the standard clinical procedure of biopsy collection for diagnostics to assist in the decision-making process. Their services and products can also identify biomarkers of clinical interest and be used to discover new targets for drug development.

Website
Key information

–  Therapeutic areas: Oncology, Cancer, Liver cancer, Colon cancer, Precision medicine, AI

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2023